Target intelligence / Profile preview

Transmembrane protein 248 pseudogene 1 (TMEM248P1)

Target
TMEM248P1
Molecular classification
Other (Pseudogene)
01

Overview

Transmembrane protein 248 pseudogene 1 (TMEM248P1) is a human pseudogene with no evidence of protein product or functional role. Pseudogenes like TMEM248P1 arise from gene duplication or retrotransposition events and typically lack the regulatory elements or intact coding sequences required for protein expression. TMEM248P1 is not considered a receptor, enzyme, transporter, or other functional molecular target and is not relevant in therapeutic contexts[2][4].

Other names
TMEM248P1

Beyond the preview

Go deeper on Transmembrane protein 248 pseudogene 1 (TMEM248P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane protein 248 pseudogene 1 (TMEM248P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call